Stem cell companies focused on the central nervous system (CNS) have the potential to address some of the largest unmet healthcare markets including: Alzheimer's disease, amyotrophic lateral sclerosis, depression, hearing loss, Huntington's disease, lysosomal storage disorders, multiple sclerosis, Parkinson's disease, retinal disorders, spinal cord injury, stroke, traumatic brain injury, and other brain and nervous system disorders.
"Our research found that there has been substantial progress in the development of neuroregenerative treatments and growing investment opportunity," said Casey Lynch Managing Director of NeuroInsights. "Stem cell company stocks in the neuroscience area were up an average of 57% over the last twelve months. There are now over 30 clinical trials involving stem cells for neuro indications. We continue to believe that stem cells along with gene therapy are two of the most promising areas of treatment development for neurological disorders."
The report covers developments at more than 100 organizations and provides in-depth profiles of twenty five companies with an especially important role in shaping the field, namely: Advanced Cell Technology, ArunA Biomedical, Athersys (NASDAQ:ATHX), Beike Biotechnology Company, BrainCells, Inc., BrainStorm Cell Therapeutics, California Stem Cell Inc., Cell Cure Neurosciences, CellMed AG, DaVinci Biosciences, Geron Corporation (NASDAQ:GERN), International Stem Cell Corporation, iPierian, NeuralStem, NeuroGeneration, NeuroNova AB, NsGene A/S, Pfizer Regenerative Medicine, Q Therapeutics, ReNeuron Group (LSE:RENE.L), RhinoCyte, SanBio, Stem Cell Technologies, StemCells, Inc. (NASDAQ:STEM), and Stemedica.
The 190 page report, "Stem Cell Approaches in Neurology and Psychiatry: 25 Trendsetters for 2011" is available immediately for purchase online or can be ordered by calling NeuroInsights at 415-229-3225.
About NeuroInsights
NeuroInsights is the world's leading neurotechnology research and advisory firm. As the neurotechnology market authority, NeuroInsights helps investors, industry and society understand and profit from the rapid growth in drugs, devices, cell-based therapeutics and diagnostics for the brain and nervous system. NeuroInsights provides market reports, investment information, industry events and strategic advisory services to venture funds, startups, corporations, governments and financial institutions. NeuroInsights created and maintains the NASDAQ(R) NeuroInsights(R) Neurotech Index (NASDAQ: NERV), an index designed to track the performance of the leading neurotechnology companies which are listed and actively traded on one of the three major U.S. stock exchanges.
Contact:
Casey Lynch,
Managing Director
clynch@neuroinsights.com
415-229-3225
www.neuroinsights.com
www.neurotechinsights.com
